Related Experiment Video
Updated: May 11, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
Identification of a Novel Structural Class of HV1 Inhibitors by Structure-Based Virtual Screening
Martina Piga1, Zoltan Varga2, Adam Feher2
1Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana 1000, Slovenia.
Insights
Researchers identified new inhibitors for the human voltage-gated proton channel (hHV1), a target for cancer and inflammatory diseases. Compound 13 and its analogs show promise for therapeutic development.
Area of Science:
- Biochemistry
- Pharmacology
- Ion Channel Biology
Background:
- The human voltage-gated proton channel (hHV1) is implicated in cancer metastasis, neuroinflammation, immune disorders, and infertility.
- Overexpression of hHV1 in cancer cells suggests its potential as a therapeutic target.
Purpose of the Study:
- To identify novel inhibitors of the hHV1 channel using structure-based virtual screening.
- To investigate the structure-activity relationships (SAR) of identified inhibitors.
- To evaluate the antiproliferative effects of hHV1 inhibitors in cancer cell lines.
Main Methods:
- Structure-based virtual screening of compounds against an open hHV1 channel structure.
- In vitro testing of virtual screening hits and analogs on hHV1-expressing CHO cells.
- Determination of IC50 values for proton current block.
- Assessment of antiproliferative activity in MDA-MB-231 and THP-1 cancer cell lines.
Main Results:
- Compound 13 demonstrated potent hHV1 channel block with an IC50 of 8.5 μM.
- Further optimization yielded six additional compounds with significant proton current inhibition.
- Compound 13 exhibited antiproliferative effects with IC50 values of 9.0 μM and 8.1 μM in MDA-MB-231 and THP-1 cells, respectively.
- Structure-activity relationship analysis provided insights into inhibitor design.
Conclusions:
- A new structural class of hHV1 inhibitors was identified.
- These findings enhance understanding of hHV1 inhibition mechanisms.
- The identified compounds represent potential leads for therapeutic strategies in cancer and other hHV1-related pathologies.
Abstract:
The human voltage-gated proton channel, hHV1, is highly expressed in various cell types including macrophages, B lymphocytes, microglia, sperm cells and also in various cancer cells. Overexpression of HV1 has been shown to promote tumor formation by highly metastatic cancer cells, and has been associated with neuroinflammatory diseases, immune response disorders and infertility, suggesting a potential use of hHV1 inhibitors in numerous therapeutic areas. To identify compounds targeting this channel, we performed a structure-based virtual screening on an open structure of the human HV1 channel. Twenty selected virtual screening hits were tested on Chinese hamster ovary (CHO) cells transiently expressing hHV1, with compound 13 showing strong block of the proton current with an IC50 value of 8.5 μM. Biological evaluation of twenty-three additional analogs of 13 led to the discovery of six other compounds that blocked the proton current by more than 50% at 50 μM concentration. This allowed for an investigation of structure-activity relationships. The antiproliferative activity of the selected promising hHV1 inhibitors was investigated in the cell lines MDA-MB-231 and THP-1, where compound 13 inhibited growth with an IC50 value of 9.0 and 8.1 μM, respectively. The identification of a new structural class of HV1 inhibitors contributes to our understanding of the structural requirements for inhibition of this ion channel and opens up the possibility of investigating the role of HV1 inhibitors in various pathological conditions and in cancer therapy.
More Related Videos
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025